EA201400914A1 - Ротавирусная субъединичная вакцина и способы ее получения и применения - Google Patents

Ротавирусная субъединичная вакцина и способы ее получения и применения

Info

Publication number
EA201400914A1
EA201400914A1 EA201400914A EA201400914A EA201400914A1 EA 201400914 A1 EA201400914 A1 EA 201400914A1 EA 201400914 A EA201400914 A EA 201400914A EA 201400914 A EA201400914 A EA 201400914A EA 201400914 A1 EA201400914 A1 EA 201400914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
production
rotavirus
subunit vaccine
rotavirus subunit
Prior art date
Application number
EA201400914A
Other languages
English (en)
Other versions
EA034564B1 (ru
Inventor
Рассел Ф. Бей
Рэнди Р. Симонсон
Камеш Редди Сириджиредди
Бенджамин Мэтью Хаус
Original Assignee
Мериал Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мериал Лимитед filed Critical Мериал Лимитед
Publication of EA201400914A1 publication Critical patent/EA201400914A1/ru
Publication of EA034564B1 publication Critical patent/EA034564B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данным изобретением предлагаются антигенные полипептиды или антигены ротавирусов, вызывающие у животных или человека иммунный ответ, направленный против ротавирусов; композиции, содержащие указанные ротавирусные полипептиды; способы вакцинации от ротавирусов и наборы для применения таких способов и композиций. Также предлагаются новые экспрессионные векторы для получения антигенных полипептидов для вакцины.
EA201400914A 2012-02-14 2013-02-14 Ротавирусная субъединичная вакцина, способ ее получения и применение EA034564B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598624P 2012-02-14 2012-02-14
PCT/US2013/026179 WO2013123219A1 (en) 2012-02-14 2013-02-14 Rotavirus subunit vaccines and methods of making and use thereof

Publications (2)

Publication Number Publication Date
EA201400914A1 true EA201400914A1 (ru) 2014-12-30
EA034564B1 EA034564B1 (ru) 2020-02-20

Family

ID=47755047

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400914A EA034564B1 (ru) 2012-02-14 2013-02-14 Ротавирусная субъединичная вакцина, способ ее получения и применение

Country Status (21)

Country Link
US (1) US9446117B2 (ru)
EP (1) EP2814508B1 (ru)
JP (1) JP6149240B2 (ru)
KR (1) KR102087458B1 (ru)
CN (1) CN104203274B (ru)
AR (2) AR089995A1 (ru)
AU (1) AU2013221479B2 (ru)
BR (1) BR112014020025B1 (ru)
CA (1) CA2864106C (ru)
DK (1) DK2814508T5 (ru)
EA (1) EA034564B1 (ru)
ES (1) ES2632429T3 (ru)
HU (1) HUE033858T2 (ru)
LT (1) LT2814508T (ru)
MX (1) MX353786B (ru)
NZ (1) NZ628282A (ru)
PH (1) PH12014501795B1 (ru)
PL (1) PL2814508T3 (ru)
PT (1) PT2814508T (ru)
SI (1) SI2814508T1 (ru)
WO (1) WO2013123219A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
RU2649132C1 (ru) * 2017-08-03 2018-03-29 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ получения активного начала вакцины против ротавирусной инфекции белка FliCVP6VP8
CN108864260A (zh) * 2018-07-17 2018-11-23 昆明学院 非结构蛋白nsp4、重组杆状病毒液及制备、粘膜佐剂
CN109306007B (zh) * 2018-09-26 2021-10-08 华中农业大学 抗猪繁殖与呼吸综合征病毒nsp4蛋白基因工程抗体及应用
US20220160864A1 (en) * 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
CA3195910A1 (en) * 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
CN114875047A (zh) * 2022-05-27 2022-08-09 江苏三仪生物工程有限公司 一种优化的猪轮状病毒外衣壳蛋白vp4的重组表达及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US5147639A (en) * 1990-06-19 1992-09-15 Ambico, Inc. Type-c rotavirus cultures and uses therefor
US5298244A (en) 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
BE1006085A3 (fr) 1992-07-31 1994-05-10 Univ Bruxelles Vecteur de clonage.
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
WO1997000088A2 (en) * 1995-06-14 1997-01-03 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
CA2327387C (en) 1998-05-07 2012-07-03 Gx Biosystems A/S Cytotoxin-based biological containment
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6716431B1 (en) 1998-05-29 2004-04-06 Wyeth Holdings Corporation Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4
US6187319B1 (en) 1998-06-01 2001-02-13 University Of Massachusetts Cross-protective rotavirus vaccine
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6867353B2 (en) 2000-02-12 2005-03-15 Exploregen Inc. Production method of recombinant rotavirus structural proteins and vaccine composition
CA2427809A1 (en) * 2000-11-03 2002-05-10 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same
CA2510189A1 (en) 2002-12-19 2004-07-08 Thomas Gore Trivalent vaccine with maternal antibody transfer via the milk
US7371395B2 (en) * 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
WO2006007555A2 (en) * 2004-07-01 2006-01-19 Children's Medical Center Corporation ¨ Rotavirus antigens
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0504441A (pt) 2005-10-20 2007-06-26 Fundacao Oswaldo Cruz vetores de expressão plasmidial contendo regiões especìficas para a expressão de proteìnas ou epìtopos recombinantes de rotavìrus e astrovìrus, processo de produção dos insumos para geração de imunobiológicos para diagnóstico
EP1991262A4 (en) * 2006-03-03 2009-11-04 Merial Ltd MYCOPLASMA HYOPNEUMONIAE VACCINE
EP2297186B1 (en) 2008-05-29 2018-08-29 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Expression and assembly of human group c rotavirus-like particles and uses thereof
CA2730741C (en) 2008-07-18 2016-10-25 Regis Sodoyer Self-replicating vector lacking an antibiotic-resistance gene
UA107940C2 (en) 2009-09-10 2015-03-10 Merial Ltd The vaccine composition that includes the saponin-containing adjuvant

Also Published As

Publication number Publication date
CN104203274A (zh) 2014-12-10
PH12014501795B1 (en) 2019-06-14
PH12014501795A1 (en) 2014-11-17
JP6149240B2 (ja) 2017-06-21
CN104203274B (zh) 2017-09-08
AR126891A2 (es) 2023-11-29
HK1200326A1 (en) 2015-08-07
SI2814508T1 (sl) 2017-10-30
AU2013221479B2 (en) 2017-06-08
HUE033858T2 (en) 2018-01-29
AU2013221479A1 (en) 2014-08-28
MX353786B (es) 2018-01-29
PL2814508T3 (pl) 2017-09-29
ES2632429T3 (es) 2017-09-13
EP2814508B1 (en) 2017-04-12
US20130209507A1 (en) 2013-08-15
EA034564B1 (ru) 2020-02-20
PT2814508T (pt) 2017-07-19
DK2814508T3 (da) 2017-05-22
EP2814508A1 (en) 2014-12-24
JP2015508776A (ja) 2015-03-23
DK2814508T5 (da) 2017-06-12
BR112014020025B1 (pt) 2022-09-27
MX2014009722A (es) 2015-02-20
KR102087458B1 (ko) 2020-03-10
US9446117B2 (en) 2016-09-20
CA2864106A1 (en) 2013-08-22
CA2864106C (en) 2017-10-17
WO2013123219A1 (en) 2013-08-22
BR112014020025A2 (pt) 2017-07-04
LT2814508T (lt) 2017-06-26
BR112014020025A8 (pt) 2022-07-12
AR089995A1 (es) 2014-10-01
NZ628282A (en) 2016-08-26
KR20140123592A (ko) 2014-10-22

Similar Documents

Publication Publication Date Title
SA519401072B1 (ar) Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها
EA201400914A1 (ru) Ротавирусная субъединичная вакцина и способы ее получения и применения
MX421186B (es) Constructos de anticuerpos.
EA201790239A1 (ru) Молекула-носитель для антигенов
PH12017500727A1 (en) Modified virus-like particles of cmv
DK3584252T3 (da) Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
IL263382A (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
HK1254344A1 (zh) 抗原匹配的流感疫苗
EP3237439A4 (en) Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
EA201691348A1 (ru) Однофлаконные вакцинные составы
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
IL273648A (en) Microbiota sequence variants of tumor-associated antigenic epitopes
EP3630172A4 (en) Compositions and methods for tumor vaccination and immunotherapy involving her antigens
ZA201805547B (en) Novel antigen for use in malaria vaccine
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
IL276661A (en) Immunogenic preparation containing staphylococcal antigens
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
MX2019007924A (es) Vacunas contra la influenza.
IN2014CN00547A (ru)
CL2013002782A1 (es) Formulación inmunogénica para inducir la respuesta inmune en un sujeto que comprende una mezcla de bacterias no patógenas que expresan cada una un segmento hipervariable de la proteína m de diferentes streptococcus pyogenes; uso de la formulación para producir una vacuna; método para producir vacuna
GB202009414D0 (en) Vaccine antigens